염산 옥시코돈 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Oxycodone Hydrochloride Market size is expected to reach USD 744.73 Million in 2034 from USD 469.09 Million (2025) growing at a CAGR of 5.27% during 2026-2034.

The Global Oxycodone Hydrochloride Market has witnessed steady growth due to the increasing prevalence of chronic pain conditions, post-surgical pain management needs, and cancer-related pain therapies. Rising geriatric populations and higher surgical volumes across developing economies are contributing significantly to market expansion. Hospitals and specialty clinics continue to rely on oxycodone-based formulations for effective pain control, particularly in moderate to severe pain cases.

Key growth drivers include improved healthcare access, expanding pharmaceutical manufacturing capabilities, and growing awareness regarding pain management therapies. However, strict regulatory frameworks and concerns over opioid misuse are influencing prescribing practices. Governments worldwide are implementing monitoring programs to ensure safe usage while maintaining access for patients with legitimate medical needs.

Looking ahead, the market is expected to grow moderately, driven by controlled-release formulations and abuse-deterrent technologies. Pharmaceutical companies are investing in safer opioid alternatives and combination therapies to reduce dependency risks. Emerging markets in Asia-Pacific and Latin America are anticipated to provide new growth opportunities, supported by healthcare infrastructure development and rising medical expenditure.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Controlled-Release
• Immediate-Release

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Eli Lilly and Company, , Gilead Sciences Inc, Manus Aktteva Biopharma LLP, Arevipharma GmbH, Saneca Pharma as, Cipla Ltd, Noramco Inc, MacFarlan Smith, Teva Pharmaceutical Industries Ltd, Taj Pharma, Chattem Chemicals Inc, Mayne Pharma Group Ltd, Dr Reddys Laboratories Limited, Siegfried, Rhodes Pharmaceuticals LP
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL OXYCODONE HYDROCHLORIDE MARKET: BY TYPE 2022-2034 (USD MN and Kilo Tons)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Controlled-Release Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 4.3. Immediate-Release Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 5. GLOBAL OXYCODONE HYDROCHLORIDE MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN and Kilo Tons)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 6. GLOBAL OXYCODONE HYDROCHLORIDE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Kilo Tons)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 7. GLOBAL OXYCODONE HYDROCHLORIDE MARKET: BY REGION 2022-2034(USD MN and Kilo Tons)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
  • 7.2.1 By Type
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
  • 7.3.1 By Type
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
  • 7.4.1 By Type
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
  • 7.5.1 By Type
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
  • 7.6.1 By Type
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL OXYCODONE HYDROCHLORIDE INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Gilead Sciences Inc
  • 9.2.2 Manus Aktteva Biopharma LLP
  • 9.2.3 Arevipharma GmbH
  • 9.2.4 Saneca Pharma A.S
  • 9.2.5 Cipla Ltd
  • 9.2.6 Noramco Inc
  • 9.2.7 MacFarlan Smith
  • 9.2.8 Teva Pharmaceutical Industries Ltd
  • 9.2.9 Taj Pharma
  • 9.2.10 Chattem Chemicals Inc
  • 9.2.11 Mayne Pharma Group Ltd
  • 9.2.12 Dr. Reddy'S Laboratories Limited
  • 9.2.13 Siegfried
  • 9.2.14 Rhodes Pharmaceuticals L.P